GlaxoSmithKline Liabilities 2024

GlaxoSmithKline Aktienanalyse

What does GlaxoSmithKline do?

GlaxoSmithKline PLC is a globally leading pharmaceutical company headquartered in London, UK. The company's history dates back to 1873 when the Burroughs Wellcome & Co firm was founded. In 2000, the company merged with Glaxo Wellcome to form the current GlaxoSmithKline PLC. GlaxoSmithKline's business model is to provide medical solutions for various diseases and health problems. The company heavily invests in research and development to develop new drugs and vaccines. It collaborates closely with government agencies, hospitals, doctors, and patient organizations to ensure better access to its products. The company is divided into three different divisions: Pharma, Vaccines, and Consumer Healthcare. The Pharma division is the largest and includes areas such as oncology, immunology, neuroscience, respiratory, and infectious diseases. GlaxoSmithKline is a leader in HIV treatment and is also active in the development of cancer drugs. The Vaccines division of GlaxoSmithKline is also very large and includes vaccines against various infectious diseases such as pneumococcus, influenza, and meningitis. It is also working on the development of vaccines against COVID-19. GlaxoSmithKline's Consumer Healthcare division includes products such as Sensodyne, Voltaren, Nicotinell, and Aquafresh. These products operate in the areas of oral health, pain relief, and smoking cessation. The focus is on a wide range of over-the-counter products available in pharmacies and supermarkets. An example of an important product of GlaxoSmithKline is the malaria vaccine developed in collaboration with the University of Oxford. The vaccine has the potential to save millions of lives in Africa. Currently, the vaccine is being tested in several African countries. GlaxoSmithKline PLC has also faced some controversies in the past, particularly related to the marketing of antidepressants. However, the company has taken measures to increase the transparency of its practices and operate ethically. Overall, GlaxoSmithKline is a significant pharmaceutical company that offers a wide range of medical products and solutions. It heavily invests in research and development to develop new products that can improve people's lives. The company also adopts an ethical approach in its business and advocates for better access to its products. GlaxoSmithKline ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing GlaxoSmithKline's Liabilities

GlaxoSmithKline's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GlaxoSmithKline's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GlaxoSmithKline's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GlaxoSmithKline's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GlaxoSmithKline’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GlaxoSmithKline stock

What is the level of liabilities of GlaxoSmithKline this year?

GlaxoSmithKline has a debt balance of 45.66 B GBP this year.

What were the liabilities of GlaxoSmithKline compared to the previous year?

The liabilities of GlaxoSmithKline have increased by -7.85% dropped compared to the previous year.

What are the consequences of high debt for investors of GlaxoSmithKline?

High liabilities can pose a risk for investors of GlaxoSmithKline, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in GlaxoSmithKline?

Low liabilities mean that GlaxoSmithKline has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of GlaxoSmithKline affect the company?

An increase in liabilities of GlaxoSmithKline can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of GlaxoSmithKline affect the company?

A decrease in the liabilities of GlaxoSmithKline can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of GlaxoSmithKline?

Some factors that can influence the liabilities of GlaxoSmithKline include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of GlaxoSmithKline so important for investors?

The liabilities of GlaxoSmithKline are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can GlaxoSmithKline take to modify the liabilities?

To change its liabilities, GlaxoSmithKline can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does GlaxoSmithKline pay?

Over the past 12 months, GlaxoSmithKline paid a dividend of 0.56 GBP . This corresponds to a dividend yield of about 3.82 %. For the coming 12 months, GlaxoSmithKline is expected to pay a dividend of 1.04 GBP.

What is the dividend yield of GlaxoSmithKline?

The current dividend yield of GlaxoSmithKline is 3.82 %.

When does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of GlaxoSmithKline?

GlaxoSmithKline paid dividends every year for the past 26 years.

What is the dividend of GlaxoSmithKline?

For the upcoming 12 months, dividends amounting to 1.04 GBP are expected. This corresponds to a dividend yield of 7.14 %.

In which sector is GlaxoSmithKline located?

GlaxoSmithKline is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline from 10/10/2024 amounting to 0.15 GBP, you needed to have the stock in your portfolio before the ex-date on 8/15/2024.

When did GlaxoSmithKline pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of GlaxoSmithKline in the year 2023?

In the year 2023, GlaxoSmithKline distributed 0.67 GBP as dividends.

In which currency does GlaxoSmithKline pay out the dividend?

The dividends of GlaxoSmithKline are distributed in GBP.